PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.07%
Negative revenue growth while Healthcare median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
822.03%
Gross profit growth of 822.03% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
-112.41%
Negative EBIT growth while Healthcare median is 2.53%. Seth Klarman would check if external or internal factors caused the decline.
-112.41%
Negative operating income growth while Healthcare median is 1.36%. Seth Klarman would check if structural or cyclical issues are at play.
85.63%
Net income growth exceeding 1.5x Healthcare median of 5.08%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
86.67%
EPS growth exceeding 1.5x Healthcare median of 7.31%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
87.78%
Diluted EPS growth exceeding 1.5x Healthcare median of 7.55%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
11.12%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
13.10%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-125.44%
Negative OCF growth while Healthcare median is -10.52%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-88.64%
Negative FCF growth while Healthcare median is -8.17%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
549.91%
5Y CAGR of 549.91% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
-39.53%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-3850.87%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-216.02%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
25.36%
3Y OCF/share growth of 25.36% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-2957.33%
Negative 10Y net income/share CAGR vs. Healthcare median of 2.15%. Seth Klarman might see a fundamental problem if peers maintain growth.
-213.57%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-299.18%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
7956.19%
Equity/share CAGR exceeding 1.5x Healthcare median of 16.56% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
304.44%
5Y equity/share CAGR > 1.5x Healthcare median of 4.56%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
30.41%
3Y equity/share CAGR > 1.5x Healthcare median of 3.03%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.22%
AR growth of 3.22% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-0.36%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
2.62%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-7.54%
Negative BV/share change while Healthcare median is -4.36%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
5.45%
Slightly rising debt while Healthcare median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
207.41%
R&D growth of 207.41% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-7.22%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.